Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 437

1.

Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics.

Vinagre I, Gerstein H, Viñals C, Conget I.

Endocrinol Diabetes Nutr. 2019 Mar 16. pii: S2530-0164(19)30035-7. doi: 10.1016/j.endinu.2019.01.005. [Epub ahead of print] English, Spanish. No abstract available.

PMID:
30890422
2.

Dysglycemia and the Density of the Coronary Vasa Vasorum.

Gerstein HC, Nair V, Chaube R, Stoute H, Werstuck G.

Diabetes Care. 2019 Mar 12. pii: dc182483. doi: 10.2337/dc18-2483. [Epub ahead of print]

PMID:
30862652
3.

Effects of basal insulin glargine and omega-3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial.

Dagenais GR, Jung H, Bogaty P, Bosch J, Yusuf S, Gerstein HC.

Diabetes Obes Metab. 2019 Feb 20. doi: 10.1111/dom.13674. [Epub ahead of print]

PMID:
30785660
4.

Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.

Boye KS, Riddle MC, Gerstein HC, Mody R, Garcia-Perez LE, Karanikas CA, Lage MJ, Riesmeyer JS, Lakshmanan MC.

Diabetes Obes Metab. 2019 Feb 3. doi: 10.1111/dom.13649. [Epub ahead of print]

PMID:
30714309
5.

Real-world studies no substitute for RCTs in establishing efficacy.

Gerstein HC, McMurray J, Holman RR.

Lancet. 2019 Jan 19;393(10168):210-211. doi: 10.1016/S0140-6736(18)32840-X. No abstract available.

PMID:
30663582
6.

Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration.

Seferovic JP, Bentley-Lewis R, Claggett B, Diaz R, Gerstein HC, Køber LV, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Pfeffer MA.

J Diabetes Res. 2018 Dec 16;2018:1631263. doi: 10.1155/2018/1631263. eCollection 2018.

7.

The Diabetes Health Coaching Randomized Controlled Trial: Rationale, Design and Baseline Characteristics of Adults Living With Type 2 Diabetes.

Sherifali D, Brozic A, Agema P, Gerstein HC, Punthakee Z, McInnes N, O'Reilly D, Ibrahim S, Usman Ali RM.

Can J Diabetes. 2018 Oct 17. pii: S1499-2671(18)30747-0. doi: 10.1016/j.jcjd.2018.10.004. [Epub ahead of print]

PMID:
30578164
8.

Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trial.

Wang A, Arver S, Boman K, Gerstein HC, Fu Lee S, Hess S, Rydén L, Mellbin LG.

Eur J Prev Cardiol. 2018 Dec 19:2047487318819142. doi: 10.1177/2047487318819142. [Epub ahead of print]

PMID:
30567457
9.

Cognitive function in adolescence and the risk for premature diabetes and cardiovascular mortality in adulthood.

Twig G, Tirosh A, Derazne E, Haklai Z, Goldberger N, Afek A, Gerstein HC, Kark JD, Cukierman-Yaffe T.

Cardiovasc Diabetol. 2018 Dec 5;17(1):154. doi: 10.1186/s12933-018-0798-5.

10.

Insulin use for type 2 diabetes: the challenges of predicting trends and modelling care.

Gerstein HC.

Lancet Diabetes Endocrinol. 2019 Jan;7(1):4-5. doi: 10.1016/S2213-8587(18)30312-7. Epub 2018 Nov 21. No abstract available.

PMID:
30470519
11.

Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial.

Cukierman-Yaffe T, Bosch J, Jung H, Punthakee Z, Gerstein HC.

Diabetes Care. 2019 Jan;42(1):142-147. doi: 10.2337/dc18-0690. Epub 2018 Nov 13.

PMID:
30425095
12.

A Mendelian Randomization-Based Approach to Identify Early and Sensitive Diagnostic Biomarkers of Disease.

Mohammadi-Shemirani P, Sjaarda J, Gerstein HC, Treleaven DJ, Walsh M, Mann JF, McQueen MJ, Hess S, Paré G.

Clin Chem. 2019 Mar;65(3):427-436. doi: 10.1373/clinchem.2018.291104. Epub 2018 Oct 18.

PMID:
30337280
13.

Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.

Morieri ML, Gao H, Pigeyre M, Shah HS, Sjaarda J, Mendonca C, Hastings T, Buranasupkajorn P, Motsinger-Reif AA, Rotroff DM, Sigal RJ, Marcovina SM, Kraft P, Buse JB, Wagner MJ, Gerstein HC, Mychaleckyj JC, Parè G, Doria A.

Diabetes Care. 2018 Nov;41(11):2404-2413. doi: 10.2337/dc18-0709. Epub 2018 Sep 27.

PMID:
30262460
14.

The association of basal insulin treatment versus standard care with outcomes in anti-GAD positive and negative subjects: A post-hoc analysis of the ORIGIN trial.

Birkeland KI, Grill V, Wium C, McQueen MJ, Lopez-Jaramillo P, Lee SF, Gerstein HC.

Diabetes Obes Metab. 2019 Feb;21(2):429-433. doi: 10.1111/dom.13528. Epub 2018 Oct 3.

PMID:
30203580
15.

Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study.

Chow CK, Ramasundarahettige C, Hu W, AlHabib KF, Avezum A Jr, Cheng X, Chifamba J, Dagenais G, Dans A, Egbujie BA, Gupta R, Iqbal R, Ismail N, Keskinler MV, Khatib R, Kruger L, Kumar R, Lanas F, Lear S, Lopez-Jaramillo P, McKee M, Mohammadifard N, Mohan V, Mony P, Orlandini A, Rosengren A, Vijayakumar K, Wei L, Yeates K, Yusoff K, Yusuf R, Yusufali A, Zatonska K, Zhou Y, Islam S, Corsi D, Rangarajan S, Teo K, Gerstein HC, Yusuf S; PURE investigators.

Lancet Diabetes Endocrinol. 2018 Oct;6(10):798-808. doi: 10.1016/S2213-8587(18)30233-X. Epub 2018 Aug 28.

PMID:
30170949
16.

Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.

ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Parish S, Armitage J.

N Engl J Med. 2018 Oct 18;379(16):1540-1550. doi: 10.1056/NEJMoa1804989. Epub 2018 Aug 26.

PMID:
30146932
17.

Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.

ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Parish S, Armitage J.

N Engl J Med. 2018 Oct 18;379(16):1529-1539. doi: 10.1056/NEJMoa1804988. Epub 2018 Aug 26.

PMID:
30146931
18.

Minimally important difference and predictors of change in quality of life in type 2 diabetes: A community-based survey in China.

Jin X, Liu GG, Gerstein HC, Levine MAH, Guan H, Li H, Xie F.

Diabetes Metab Res Rev. 2018 Nov;34(8):e3053. doi: 10.1002/dmrr.3053. Epub 2018 Aug 31.

PMID:
30064154
19.

Association of preoperative glucose concentration with myocardial injury and death after non-cardiac surgery (GlucoVISION): a prospective cohort study.

Punthakee Z, Iglesias PP, Alonso-Coello P, Gich I, India I, Malaga G, Jover RD, Gerstein HC, Devereaux PJ.

Lancet Diabetes Endocrinol. 2018 Oct;6(10):790-797. doi: 10.1016/S2213-8587(18)30205-5. Epub 2018 Jul 26.

PMID:
30057170
20.

Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease.

Sjaarda J, Gerstein H, Chong M, Yusuf S, Meyre D, Anand SS, Hess S, Paré G.

J Am Coll Cardiol. 2018 Jul 17;72(3):300-310. doi: 10.1016/j.jacc.2018.04.067. Epub 2018 Jul 9.

PMID:
30012324

Supplemental Content

Loading ...
Support Center